TABLE 1. Characteristics of recombinant zoster vaccine (RZV) reports submitted to VAERS — United States, October 2017–June 2018.
| Report characteristic | No. (%) |
|---|---|
|
Total reports
|
4,381 (100)
|
|
Sex
| |
| Women |
2,870 (65.5) |
| Men |
1,265 (28.9) |
| Not reported or unknown |
246 (5.6) |
|
Seriousness*
| |
| Nonserious |
4,251 (97.0) |
| Serious† |
130 (3.0) |
|
Type of reporter
| |
| Health care professional |
1,661 (37.9) |
| Manufacturer |
1,661 (37.9) |
| Patient |
801 (18.3) |
| Other |
236 (5.4) |
| Parent/Guardian/Caretaker |
22 (0.5) |
|
Age group (yrs)
| |
| <50§ |
27 (0.6) |
| 50–59 |
956 (21.8) |
| 60–69 |
1,467 (33.5) |
| 70–79 |
988 (22.6) |
| ≥80 |
251 (5.7) |
| Not reported or unknown |
692 (15.8) |
| RZV given alone¶ | 4,167 (95.1) |
Abbreviation: VAERS = Vaccine Adverse Event Reporting System.
* Includes hospitalization, prolongation of existing hospitalization, life-threatening illness, permanent disability, congenital anomaly or birth defect, and death, as defined in Code of Federal Regulations Title 21 Section 600.80.
† Includes eight reports of death, seven of which were confirmed using autopsy reports, death certificates, or medical records; one was an unconfirmed hearsay (i.e., secondhand) report.
§ RZV is not licensed for use in this age group.
¶ When RZV was given concomitantly with other vaccines, the most common vaccines included 23-valent pneumococcal polysaccharide (86); tetanus, diphtheria, acellular pertussis (Tdap), tetanus, diphtheria (Td), or tetanus toxoid (TT) (57 tetanus toxoid–containing vaccines); 13-valent pneumococcal conjugate (43); influenza (19); hepatitis A (16); and combination hepatitis A and B (seven) vaccines.